Statins and Their Effect on PCSK9-Impact and Clinical Relevance.
OBJECTIVE
To review the interactions between statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.


RESULTS
Statins are highly effective for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular disease (CVD). However, statins also raise levels of PCSK9, a protein that increases circulating LDL-C levels by increasing LDL-C receptor degradation. Increases in PCSK9 levels also reduce the LDL-C response to statin therapy. The interactions between statins, PCSK9, LDL-C, and cardiovascular risk are multifaceted and are influenced by genetic, lifestyle, and environmental factors as well as lipid-lowering therapies.
Department of Kinesiology, University of Connecticut, Gampel Pavilion Room 207, 2095 Hillside Rd, U-1110, Storrs, CT, 06269-1110, USA. Beth.Taylor@uconn.edu.|Division of Cardiology, Henry Low Heart Center, Hartford Hospital, Hartford, CT, USA. Beth.Taylor@uconn.edu.|University of Connecticut School of Medicine, Farmington, CT, USA. Beth.Taylor@uconn.edu.
Beth A
BA
Taylor
Division of Cardiology, Henry Low Heart Center, Hartford Hospital, Hartford, CT, USA. Paul.Thompson@hhchealth.org.|University of Connecticut School of Medicine, Farmington, CT, USA. Paul.Thompson@hhchealth.org.
Paul D
PD
Thompson
D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000201:enzymology; D003402:Creatine Kinase / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D050356:Lipid Metabolism / Q000187:drug effects; D000091362:PCSK9 Inhibitors; D000071449:Proprotein Convertase 9 / Q000378:metabolism*; D012307:Risk Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000091362:PCSK9 Inhibitors; D003402:Creatine Kinase; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9
Creatine kinase; Myopathy; Statin myalgia